SCHEMBL1102881

SCHEMBL1102881

c1ccc2c(-c3ccc4c5c(cccc35)CC4)c3ncccc3c(-c3ccc4c5c(cccc35)CC4)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.51
CYP11B1 P15538 2/20 0.51
KDM4E B2RXH2 8/20 0.40
ALDH1A1 P00352 6/20 0.40
HPGD P15428 5/20 0.40
MAPT P10636 5/20 0.40
KMT2A Q03164 3/20 0.40
GAA P10253 3/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 3/20 0.37
MAPK1 P28482 1/20 0.37
CYP3A4 P08684 1/20 0.36
ALOX15 P16050 1/20 0.36
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
TDP1 Q9NUW8 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103069 0.92 CYP11B1 (0.53) CYP11B2CYP11B1KDM4EALDH1A1HPGD
SCHEMBL1102934 0.81 CRHBP (0.42) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL1102733 0.78 CCR1 (0.40) KDM4EALDH1A1HPGDMAPTGAA
SCHEMBL1102535 0.78 CYP11B1 (0.60) CYP11B2CYP11B1KDM4EALDH1A1HPGD
SCHEMBL1103232 0.77 ALDH1A1 (0.40) KDM4EALDH1A1HPGDMAPTGAA
SCHEMBL1103090 0.76 KDM4E (0.45) KDM4EALDH1A1HPGDMAPTGAA
SCHEMBL1102930 0.74 CKS1B (0.49) KDM4EMAPTLMNASMN1; SMN2CYP3A4
SCHEMBL1102865 0.74 KDM4E (0.47) KDM4EALDH1A1HPGDMAPTGAA
SCHEMBL1103233 0.74 KDM4E (0.39) KDM4EALDH1A1HPGDMAPTKMT2A
SCHEMBL1103279 0.74 CYP11B2 (0.46) CYP11B2CYP11B1KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 CYP11B2 652/4885CYP11B1 836/4885KDM4E 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.